Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

December 31, 2014

Conditions
Crohn's Disease
Interventions
DRUG

Placebo

Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks

DRUG

Placebo

Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days

DRUG

BMS-936557 (Anti-IP-10 Antibody)

Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks

DRUG

BMS-936557 (Anti-IP-10 Antibody)

Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks

DRUG

BMS-936557 (Anti-IP-10 Antibody)

Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days

DRUG

BMS-936557 (Anti-IP-10 Antibody)

Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days

DRUG

BMS-936557 (Anti-IP-10 Antibody)

Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open

Trial Locations (33)

1083

Local Institution, Budapest

1088

Local Institution, Budapest

1090

Local Institution, Brussels

3000

Local Institution, Leuven

4012

Local Institution, Debrecen

4091

Local Institution, Overport

7506

Local Institution, Panorama

7708

Local Institution, Claremont

10029

Mount Sinai School Of Medicine, New York

11021

Nyu Langone Long Island Clinical Research Associates, Great Neck

16100

Local Institution, Nazareth

20815

Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr, Chevy Chase

27599

University Of North Carolina At Chapel Hill, Chapel Hill

31048

Local Institution, Haifa

32789

Shafran Gasteroenterology Center, Winter Park

33064

Local Institution, Pessac

44281

Local Institution, Kfar Saba

45219

Consultants For Clinical Research, Cincinnati

54511

Local Institution, Vandœuvre-lès-Nancy

64064

Midwest Center For Clinical Research, Lees Summit

70403

Gastroenterology Research Of New Orleans, Hammond

76031

Local Institution, Rouen

78229

Gastroenterology Research Of San Antonio, San Antonio

80054

Local Institution, Amiens

90404

Southern California Medical Gastroenterology Group, Santa Monica

92110

Local Institution, Clichy

06200

Local Institution, Nice

H-1115

Local Institution, Budapest

31-501

Local Institution, Krakow

35-068

Local Institution, Rzeszów

02-507

Local Institution, Warsaw

03-580

Local Institution, Warsaw

00936

University Of Puerto Rico School Of Medicine, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01466374 - Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease | Biotech Hunter | Biotech Hunter